The short version of LC-MS/MS fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-11-19 and is reviewed periodically as new material appears.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Visual inspection is not sufficient for identity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water. |
| Typical storage | -20 °C, desiccated, dark | Protect from repeated temperature changes. |
| Common analytical method | LC-MS or HPLC-UV | Reference standard required for comparison. |
| Common synonyms | SR9009; Stenabolic; REV-ERB agonist | Vendor naming may vary. |
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
The god Hermes provides the male character Trygaios a female companion; when Trygaios asks if there would be a problem if she became pregnant, Hermes responds, "Not if you add a dose of pennyroyal." In a similar manner, in Aristophanes' comedy Lysistrata, after a pregnant female character on stage is told to withhold her body sexually from her husband, a slender female character, in comparison to the pregnant woman, is described as "a very lovely land Well croppy, and trimmed and spruced with pennyroyal." Early settlers in colonial Virginia used dried pennyroyal to eradicate pests. Pennyroyal was such a popular herb that the Royal Society published an article on its use against rattlesnakes in the first volume of its Philosophical Transactions in 1665. 17th-century apothecary and physician Nicholas Culpeper mentions pennyroyal in his medical text The English Physitian, published in 1652. In addition to its abortive properties, Culpeper recommends its use for gastrointestinal ailments, such as constipation and hemorrhoids, as well as itching and blemishes to the skin, and even toothaches. Pennyroyal is an essential ingredient in the North African dish, which is still eaten to this day, called Batata fliou. Pennyroyal continues to be used up through the 20th and 21st centuries. Its oil is still commercially available today, though little is known about the appropriate dosages for humans. Scientists therefore likely consider it unsafe for use, as it is potentially toxic.
The WHO is responsible for providing the CND with the scientific evidence and recommendations used in determining drug scheduling and evaluating proposed treaty amendments. This work is carried out by the WHO Expert Committee on Drug Dependence (ECDD), a chosen group of independent experts within the field of pharmacology. The ECDD evaluates drugs for potential for harm including addiction, and for possible medical value.
The term "isotope", Greek for "at the same place", was suggested to Soddy by Margaret Todd, a Scottish physician and family friend, during a conversation in which he explained his ideas to her. He received the 1921 Nobel Prize in Chemistry in part for his work on isotopes.
== History == The first successful mechanically refrigerated trucks were made for the ice cream industry in 1925. American inventor Frederick McKinley Jones is known to be the first person to invent a refrigerated truck. There were around 4 million refrigerated road vehicles in use in 2010 worldwide.
Sources: en.wikipedia.org
===== Other names in the Western world ===== In the last decades, two new important terminologies emerged. Both are commonly used in the Western world in neoshamanic, recreative or pharmaceutical contexts to address ayahuasca-like substances created without the traditional botanical species, due to it being expensive and/or hard to find in these countries. These concepts are surrounded by some controversies involving ethnobotany, patents, commodification and biopiracy:
== Controversies and criticism == In 2006, when he was a professor at the MIT Media Lab, Ariely conducted experiments including administering electric shocks with a research assistant who had no human-subject training. As a consequence, MIT's ethics committee banned Ariely from supervising data collection for a year. Ariely confirmed this and said that he was not aware that the research assistant did not have the needed one-hour online human-subject training. In 2021, a 2012 paper written by Francesca Gino, Max H. Bazerman, Nina Mazar, Lisa L Shu, and Ariely was discovered to be based on falsified data and was subsequently retracted. In 2024, Ariely told Business Insider that Duke had completed a three-year investigation that, according to him, concluded that data from the paper had been falsified but found no evidence that Ariely had used fake data knowingly. Duke University declined to comment on the grounds that their procedure is not to comment. In a 2024 LinkedIn article posted to his account, Ariely argued that he was able to replicate the findings in two papers he co-authored. In July 2021, the journal Psychological Science challenged a 2004 paper by James Heyman and Ariely, "prompted by some uncertainty regarding the values of statistical tests reported in the article and the analytic approach taken to the data". The authors were unable to resolve the ambiguities, because the original participant-level data was no longer available.
=== Hemoglobin A1c === Hemoglobin A1c is a measure of the percent of red blood cells that are glycated, or have a glucose molecule attached. This can be used as an indicator of blood glucose level over a longer period of time and is often used to diagnose prediabetes as well as diabetes. HbA1c may not accurately represent blood glucose levels and should not be used in certain medical conditions such as iron-deficiency anemia, Vitamin B12 and folate deficiency, pregnancy, hemolytic anemia, an enlarged spleen, and end-stage kidney failure.
This change in infrastructure may alter cell shape and behavior and is often used to transport vesicles, pathogens, or other related structures. Actin filament crosslinking Results in the overall stabilization of the actin filament network. The cell utilizes crosslinking proteins are various sizes to accomplish different means of stability within the binding network. Relatively small ABP's such as scruin, fimbrin, and espin function by solidifying actin filament bundles. Larger ABPs that exhibit coil-like qualities such as filament function in the promotion of orthogonal organization. As a whole, actin crosslinking provides framework for which the cell may transport signaling intermediates needed for other steps within the actin remodeling cycle. Actin filament contraction and cargo motoring Represents the ability for the actin filament network to react to environmental conditions and respond through various forms of vesicle and signal trafficking. Most commonly, the myosin protein exists as a "motor" that escorts cellular "cargo" throughout the cell. Myosin, primarily Myosin II, is also essential to the generation of contractile forces amongst the actin filaments. Membrane attachment to actin network Attachment of the actin-orthogonal network to the cell's membrane proves essential to the locomotion, shape, and mechanical function of the cell. The dynamic nature of a cell remains directly related to the actin-filament network's ability to respond to the contractile forces that result from environmental and internal cues.
=== Polymerization === Fluoroalkenes polymerize more exothermically than normal alkenes. Unsaturated fluorocarbons have a driving force towards sp3 hybridization due to the electronegative fluorine atoms seeking a greater share of bonding electrons with reduced s character in orbitals. The most famous member of this class is tetrafluoroethylene, which is used to manufacture polytetrafluoroethylene (PTFE), better known under the trade name Teflon.
Sources: en.wikipedia.org
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.
The solid is usually kept desiccated at -20 °C or lower and protected from light. Stock solutions are aliquoted to limit freeze–thaw cycles. Aqueous solutions are not generally recommended for long-term storage.
Laws differ by country and by intended use. It is not an approved medicine, and many vendors sell it as a research chemical. Purchasers are responsible for confirming local restrictions.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.